<?xml version="1.0" encoding="UTF-8"?>
<p>The WHO recommendation on the use of fractional doses was based on a limited number of clinical studies and important data gaps remain 
 <sup>
  <xref rid="ref-2" ref-type="bibr">2</xref>, 
  <xref rid="ref-29" ref-type="bibr">29</xref>â€“ 
  <xref rid="ref-32" ref-type="bibr">32</xref>
 </sup>. Key research priorities formulated by the WHO include: 1) determining the applicability of fractional dosing to all four WHO-prequalified vaccines, 2) the persistence of vaccine-induced neutralizing antibodies, 3) the performance of fractional doses in young children and in populations in Africa, including HIV-infected individuals and, 4) the incidences of adverse events and serious advance events 
 <sup>
  <xref rid="ref-33" ref-type="bibr">33</xref>, 
  <xref rid="ref-34" ref-type="bibr">34</xref>
 </sup>. The study protocol described here is aimed at addressing these knowledge gaps through two multicentre randomized, double-blinded, controlled non-inferiority trials in adults and children.
</p>
